This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Intellipharmaceutics Announces Second Quarter 2014 Results

TORONTO, July 7, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2014. All dollar amounts referenced herein are in United States dollars unless otherwise noted.

Revenue related to the Company's license and commercialization agreement with Par Pharmaceutical, Inc. ("Par") in the three months ended May 31, 2014 was $1.5 million versus $Nil in the three months ended May 31, 2013. The revenue in the three months ended May 31, 2014 derived principally from commercial sales of its first product, 15 and 30 mg strengths of dexmethylphenidate hydrochloride extended-release capsules (generic Focalin XR®).

Loss from operations for the three months ended May 31, 2014 was $3.1 million compared with loss from operations of $1.8 million for the three months ended May 31, 2013. Research and development ("R&D") expenditures in the three months ended May 31, 2014 increased to $3.4 million compared to $0.9 million in the three months ended May 31, 2013, primarily due to an increase in stock-based compensation expense of $1.2 million for R&D employees related to the shareholder –approved two year extension of the expiry date of previously-granted performance-based stock options to September 2016 and newly granted stock options issued to R&D executive officers. After adjusting for stock-based compensation, expenditures for R&D were higher by $1.4 million during the 2014 period. During the quarter ended May 31, 2014, the Company incurred increased expenses on furthering the development of several generic and NDA 505(B)(2) product candidates, payment of bonuses to certain R&D executive officers, and salary increases to certain non-management R&D employees. Selling, general and administrative expenses for the three months ended May 31, 2014 increased to $1.1 million versus $0.8 million in the prior period. After adjusting for stock-based compensation expense, expenditures for selling, general and administrative expenses were higher by $0.2 million during the 2014 period, primarily due to salary increases for certain non-management employees, and the payment of bonuses to certain management employees.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.04 0.43%
FB $118.09 -0.40%
GOOG $696.79 -0.20%
TSLA $235.09 -2.80%
YHOO $36.15 -1.00%


Chart of I:DJI
DOW 17,718.72 -172.44 -0.96%
S&P 500 2,058.94 -22.49 -1.08%
NASDAQ 4,762.3140 -55.28 -1.15%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs